BackUniverse Pharmaceuticals INC Overview

Universe Pharmaceuticals INC Total Liabilities

Latest total liabilities for UPC: $16M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$15.82M
37.91% YoYΔ $-9.66M vs prior year quarter

Peer trimmed avg / median

Loading

Universe Pharmaceuticals INC Total Liabilities History

Loading

Universe Pharmaceuticals INC vs. peers: Total Liabilities Comparison

Loading

Universe Pharmaceuticals INC Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Universe Pharmaceuticals INC (UPC) FAQ

Universe Pharmaceuticals INC's total liabilities stands at $16M as of March 2026. That compares with $25M in the prior-year period — down 37.9% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Universe Pharmaceuticals INC reported $16M in total liabilities versus $25M a year earlier — a 37.9% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $25M in the prior-year period — down 37.9% year over year. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Universe Pharmaceuticals INC's total liabilities evolved across reporting periods, while the comparison chart places UPC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total liabilities is commonly used to spot outliers. Universe Pharmaceuticals INC's reading of $16M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.